Showing 2871-2880 of 3876 results for "".
- InMode Launches Triton Multi-Wavelength Hair Removal Laserhttps://modernaesthetics.com/news/inmode-launches-triton-multi-wavelength-hair-removal-laser/2472069/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company say
- Evolus Appoints Michael Mazen Jafar Chief Marketing Officerhttps://modernaesthetics.com/news/evolus-appoints-michael-mazen-jafar-chief-marketing-officer/2472075/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- Revance Vet Tapped as New Evolus CFOhttps://modernaesthetics.com/news/revance-vet-tapped-as-new-evolus-cfo/2472086/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- Investigational Neurotoxin Achieves 6-Month Duration in Phase 3: Revancehttps://modernaesthetics.com/news/investigational-neurotoxin-achieves-6-month-duration-in-phase-3-revance/2472157/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared generally safe an
- Congrats! Lisa M. Donofrio, MD Named New ASDS/ASDSA Presidenthttps://modernaesthetics.com/news/congrats-lisa-m-donofrio-md-named-new-asdsasdsapresident/2472179/Lisa M. Donofrio, MD, is the new President of the American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA). Along with her fellow officers and the ASDS / ASDSA
- Cutera's truSculpt May Help Reduce Fat in the Lower Facehttps://modernaesthetics.com/news/cuteras-trusculpt-may-help-reduce-fat-in-the-lower-face/2472193/Static type monopolar 1-MHz radiofrequency may help reduce fat and tighten skin in the lower face, according to research published in Lasers in Surgery and Medicine. “We objectively observed a volumetri
- Allergan CEO Calls for Consensus on Medical Aesthetic Treatment in Minorshttps://modernaesthetics.com/news/allergan-ceo-calls-for-consensus-on-medical-aesthetic-treatment-in-minors/2472213/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- Alma Lasers Inc. Hair Removal Platform Now Comprises Three Wavelengthshttps://modernaesthetics.com/news/alma-lasers-inc-hair-removal-platform-now-comprises-three-wavelengths/2472221/Alma Lasers now offers 1064 Nd: YAG capabilities along with 810nm and 755nm on its Soprano ICE platform, allowing users to better match wavelength to hair removal patient. Alma added Alexandrite technology to its Soprano ICE platform in 2014 for
- New AAFPRS Data: More Than 30 Percent of Men Are Considering Nips and Tuckshttps://modernaesthetics.com/news/new-aafprs-data-more-than-30-percent-of-men-are-considering-nips-and-tucks/2472223/The plastic surgery ‘menaissaince’ may really be a thing, finds a new survey from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). It turns out that 31 percent of men said they are “extremely likely&rdq